Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Interpatient Variability in Mesothelin Expression Necessitates Its Evaluation Before Gastric Cancer Immunotherapy Publisher Pubmed



Sotoudeh M1 ; Mansouri V2 ; Shakeri R3 ; Sharififard B3 ; Sajadi N4 ; Naderi M2
Authors

Source: Immunotherapy Published:2022


Abstract

Aims: Mesothelin (MSLN) was applied for the immunotherapy of ovarian cancer and mesothelioma with a minimum expression of 60% to obtain a clinical response. Here, the authors evaluated MSLN expression as a potential target of gastric adenocarcinoma immunotherapy. Materials & methods: The expression of MSLN was evaluated by immunohistochemistry and was reported in primary tumor (PT) and metastatic tumor (MT) sites. Results: The results showed that only 17.1% and 13.5% of the patients had 60% or more MSLN expression in PT and MT sites, respectively. The expression of MSLN in PTs and MTs was not influenced by Lauren classification, neoadjuvant therapy or tumor stage. Conclusions: Interpatient variability in MSLN expression necessitates its evaluation before MSLN-based gastric cancer immunotherapy. © 2022 Future Medicine Ltd.
Related Docs
View other Related Docs
1. Decoding the Expression Pattern of Muc3a in Gastric Adenocarcinoma: Unveiling the Key to Successful Immunotherapy, Expert Opinion on Therapeutic Targets (2023)
2. Antxr1 (Tem8) Overexpression in Gastric Adenocarcinoma Makes the Protein a Potential Target of Immunotherapy, Cancer Immunology# Immunotherapy (2019)
3. Msln (Mesothelin), Antxr1 (Tem8), and Muc3a Are the Potent Antigenic Targets for Car T Cell Therapy of Gastric Adenocarcinoma, Journal of Cellular Biochemistry (2019)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (5)
Hamid Reza Mirzaei (4)
Other Related Docs
4. Construction and Functional Characterization of a Fully Human Anti-Mesothelin Chimeric Antigen Receptor (Car) Expressing T Cell, Iranian Journal of Allergy# Asthma and Immunology (2020)
5. Melatonin for Gastric Cancer Treatment: Where Do We Stand?, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
6. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
7. Simultaneous Targeting of Tim3 and A2a Receptors Modulates Msln-Car T Cell Antitumor Function in a Human Cervical Tumor Xenograft Model, Frontiers in Immunology (2024)
8. Differential Expression Pattern of Epithelial Mesenchymal Transition Gens: Axl, Gas6, Claudin-1, and Cofilin-1, in Different Stages of Epithelial Ovarian Cancer, Iranian Journal of Public Health (2019)
9. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
10. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
11. Genetic and Pharmacological Targeting of A2a Receptor Improves Function of Anti-Mesothelin Car T Cells, Journal of Experimental and Clinical Cancer Research (2020)
12. Anti-Tumor Activity of Neratinib, a Pan-Her Inhibitor, in Gastric Adenocarcinoma Cells, European Journal of Pharmacology (2019)
13. Evaluation of the Anti-Tumor Effects of an Anti-Human Epidermal Growth Factor Receptor 2 (Her2) Monoclonal Antibody in Combination With Cd11b+/Gr-1+ Myeloid Cells Depletion Using a Recombinant Peptibody in 4 T1-Her2 Tumor Model, International Immunopharmacology (2023)
14. Combining Nanotechnology and Gas Plasma As an Emerging Platform for Cancer Therapy: Mechanism and Therapeutic Implication, Oxidative Medicine and Cellular Longevity (2021)
15. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
16. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
17. Tumor-Infiltrating Lymphocyte Therapy for Lung Cancer and Its Future Paradigms, Expert Opinion on Biological Therapy (2022)
18. Survival Benefit of Induction Chemotherapy With Paclitaxel and Carboplatin Followed by Chemoradiation Versus Postoperative Treatment in Locally Advanced Gastric Cancer: A Retrospective Cohort Study, Journal of Gastrointestinal Cancer (2024)
19. Human Epidermal Growth Factor Receptor 2 [Her-2/Neu] Amplification and Microsatellite Stable Status in Gastric and Gastroesophageal Adenocarcinoma: Assessing Frequency and Prognostic Implications at the Cancer Institute of Iran, Cancer Reports (2025)
20. Relationship of Amplification and Expression of the C-Myc Gene With Survival Among Gastric Cancer Patients, Asian Pacific Journal of Cancer Prevention (2015)